Vickie Reed's most recent trade in Evoke Pharma Inc was a trade of 1,250 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Evoke Pharma Inc | Vickie W. Reed | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 1,250 | 8,333 | - | - | Stock Option (Right to Buy) | |
| Evoke Pharma Inc | Vickie W. Reed | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 5,833 | 5,833 | - | - | Stock Option (Right to Buy) | |
| Evoke Pharma Inc | Vickie W. Reed | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Evoke Pharma Inc | Vickie W. Reed | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| DMK Pharmaceuticals Corp | Vickie S. Reed | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 50,000 | 50,000 | - | - | Stock Appreciation Right | |
| Evoke Pharma Inc | Vickie S. Reed | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2022 | 58,000 | 58,000 | - | - | Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Vickie S. Reed | SVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 8,910 | 8,910 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Vickie S. Reed | SVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 5,377 | 15,902 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | Vickie S. Reed | SVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 120.48 per share. | 14 Jan 2022 | 533 | 15,369 (0%) | 0% | 120.5 | 64,217 | Common Stock |
| Mirati Therapeutics Inc | Vickie S. Reed | SVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 147.74 per share. | 04 Jan 2022 | 758 | 10,870 (0%) | 0% | 147.7 | 111,987 | Common Stock |
| Mirati Therapeutics Inc | Vickie Reed | SVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 6,499 | 6,499 | - | - | Employee Stock Option (Right to Buy) | |
| Mirati Therapeutics Inc | Vickie Reed | SVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 4,157 | 11,628 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | Vickie Reed | SVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 210.28 per share. | 06 Jan 2021 | 527 | 7,712 (0%) | 0% | 210.3 | 110,818 | Common Stock |
| Mirati Therapeutics Inc | Vickie Reed | SVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 216.33 per share. | 06 Jan 2021 | 241 | 7,471 (0%) | 0% | 216.3 | 52,135 | Common Stock |
| Mirati Therapeutics Inc | Vickie Reed | SVP, Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 215.73 per share. | 06 Jan 2021 | 11 | 8,239 (0%) | 0% | 215.7 | 2,373 | Common Stock |
| Mirati Therapeutics Inc | Vickie Reed | SVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Nov 2020 | 2,522 | 2,522 | - | - | Option Grant (Right to Buy) |